These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30589188)

  • 21. Dr. PIAS 2.0: an update of a database of predicted druggable protein-protein interactions.
    Sugaya N; Kanai S; Furuya T
    Database (Oxford); 2012; 2012():bas034. PubMed ID: 23060433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges in Discovering Drugs That Target the Protein-Protein Interactions of Disordered Proteins.
    Oláh J; Szénási T; Lehotzky A; Norris V; Ovádi J
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hierarchical graph learning for protein-protein interaction.
    Gao Z; Jiang C; Zhang J; Jiang X; Li L; Zhao P; Yang H; Huang Y; Li J
    Nat Commun; 2023 Feb; 14(1):1093. PubMed ID: 36841846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data.
    Sugaya N; Ikeda K; Tashiro T; Takeda S; Otomo J; Ishida Y; Shiratori A; Toyoda A; Noguchi H; Takeda T; Kuhara S; Sakaki Y; Iwayanagi T
    BMC Pharmacol; 2007 Aug; 7():10. PubMed ID: 17705877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stabilization of Protein-Protein Interactions in chemical biology and drug discovery.
    Bier D; Thiel P; Briels J; Ottmann C
    Prog Biophys Mol Biol; 2015 Oct; 119(1):10-9. PubMed ID: 26093250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-Barr Virus: Human Interactome Reveals New Molecular Insights into Viral Pathogenesis for Potential Therapeutics and Antiviral Drug Discovery.
    Krishnan D; Babu S; Raju R; Veettil MV; Prasad TSK; Abhinand CS
    OMICS; 2024 Jan; 28(1):32-44. PubMed ID: 38190109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Protein-Protein Interaction Inhibitors by Integrating Protein Engineering and Chemical Screening Platforms.
    Maculins T; Garcia-Pardo J; Skenderovic A; Gebel J; Putyrski M; Vorobyov A; Busse P; Varga G; Kuzikov M; Zaliani A; Rahighi S; Schaeffer V; Parnham MJ; Sidhu SS; Ernst A; Dötsch V; Akutsu M; Dikic I
    Cell Chem Biol; 2020 Nov; 27(11):1441-1451.e7. PubMed ID: 32726587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulating protein-protein interactions: the potential of peptides.
    Nevola L; Giralt E
    Chem Commun (Camb); 2015 Feb; 51(16):3302-15. PubMed ID: 25578807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity.
    Smith MC; Gestwicki JE
    Expert Rev Mol Med; 2012 Jul; 14():e16. PubMed ID: 22831787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noncellular screening for the discovery of protein-protein interaction modulators.
    Kieffer C; Jourdan JP; Jouanne M; Voisin-Chiret AS
    Drug Discov Today; 2020 Sep; 25(9):1592-1603. PubMed ID: 32682931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein-protein complexes as targets for drug discovery against infectious diseases.
    Akhter Y; Hussain R
    Adv Protein Chem Struct Biol; 2020; 121():237-251. PubMed ID: 32312423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicted binding site information improves model ranking in protein docking using experimental and computer-generated target structures.
    Maheshwari S; Brylinski M
    BMC Struct Biol; 2015 Nov; 15():23. PubMed ID: 26597230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the relationship between hub proteins and drug targets based on GO and intrinsic disorder.
    Fu Y; Guo Y; Wang Y; Luo J; Pu X; Li M; Zhang Z
    Comput Biol Chem; 2015 Jun; 56():41-8. PubMed ID: 25854804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. State of the art in protein-protein interactions within the fungi kingdom.
    Santos TG; Silva KS; Lima RM; Silva LC; Pereira M
    Future Microbiol; 2023 Nov; 18():1119-1131. PubMed ID: 37540069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enabling systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform.
    Mo XL; Luo Y; Ivanov AA; Su R; Havel JJ; Li Z; Khuri FR; Du Y; Fu H
    J Mol Cell Biol; 2016 Jun; 8(3):271-81. PubMed ID: 26578655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein-protein interaction inhibitors: advances in anticancer drug design.
    Ferreira LG; Oliva G; Andricopulo AD
    Expert Opin Drug Discov; 2016 Oct; 11(10):957-68. PubMed ID: 27554357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery.
    Macalino SJY; Basith S; Clavio NAB; Chang H; Kang S; Choi S
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30082644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays.
    Gul S; Hadian K
    Expert Opin Drug Discov; 2014 Dec; 9(12):1393-404. PubMed ID: 25374163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of protein-protein interactions using designed molecules.
    Wilson AJ
    Chem Soc Rev; 2009 Dec; 38(12):3289-300. PubMed ID: 20449049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein Domain Mimics as Modulators of Protein-Protein Interactions.
    Sawyer N; Watkins AM; Arora PS
    Acc Chem Res; 2017 Jun; 50(6):1313-1322. PubMed ID: 28561588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.